EGFR and non-small cell lung carcinoma: Due to our interest in EMT-associated resistance and the pro-epithelial actions of 1,25(OH)2D3, our current efforts are aimed at developing a clinically relevant orthotopic model of EGFR-mutant, TKI-resistant NSCLC.